Wakamoto Pharmaceutical Co., Ltd. (4512) AI Stock Analysis

• Market Cap: ¥10.13B
• Dividend Yield: 1.04%
• Average Volume (3M): 65.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.27
• Revenue Growth: 4.00%
• EPS Growth: -933.04%
• Country: JP
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -3.12
• Shares Outstanding: 34,838,326
• 10 Day Avg. Volume: 55,010
• 30 Day Avg. Volume: 65,936
• PEG Ratio: -4.19
• Price to Book (P/B): 0.95
• Price to Sales (P/S): 1.41
• P/FCF Ratio: -10.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 48 Neutral
• Price Target: ¥288.00 ▼(-0.35% Downside)

The overall stock score of 48 reflects the company's mixed financial performance, with a strong balance sheet but declining profitability and liquidity challenges. Technical analysis indicates potential bearish trends, and valuation is a concern due to a negative P/E ratio. The modest dividend yield provides some support but is not sufficient to significantly enhance the score.

Wakamoto Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Wakamoto Pharmaceutical Co., Ltd. (4512) is a Japan-based company engaged in the research, development, manufacture, and sale of pharmaceutical products. The company operates primarily in the healthcare sector, focusing on prescription medications, over-the-counter (OTC) drugs, and health supplements. With a commitment to innovation and quality, Wakamoto develops products that address various therapeutic areas, including gastrointestinal disorders, respiratory diseases, and nutritional support.

How the Company Makes Money

Wakamoto Pharmaceutical generates revenue through multiple streams, primarily from the sales of its pharmaceutical products, which include prescription medications and OTC drugs. The company benefits from a diversified product portfolio that caters to different therapeutic areas, thereby broadening its market reach. Additionally, Wakamoto may engage in partnerships with healthcare providers and other pharmaceutical companies for research and development collaborations, which can lead to shared revenues from new product launches. Furthermore, the company likely capitalizes on licensing agreements and regulatory approvals to expand its market presence, contributing to its overall earnings.

Wakamoto Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Wakamoto Pharmaceutical Co., Ltd. shows a mixed financial performance. The balance sheet is strong with a low debt-to-equity ratio, but the income statement reflects declining profitability, and the cash flow statement reveals liquidity challenges. Strategic improvement is needed in operational efficiency and cash management.

Income Statement

The company faces fluctuating revenue trends with a slight increase from 2024 to 2025 but a decline over the long term. Gross profit margin remains stable but with decreasing net income, leading to declining net profit margins. Despite improvement in EBITDA margin, the EBIT margin remains negative, indicating operating inefficiency.

Balance Sheet

The balance sheet shows a robust equity position with a low debt-to-equity ratio, highlighting financial stability. However, the return on equity is diminishing due to declining net income. The equity ratio remains healthy, reflecting reliable asset management.

Cash Flow

Cash flow analysis indicates challenges with negative operating cash flow and free cash flow, raising concerns about cash management. The operating cash flow to net income and free cash flow to net income ratios suggest inefficiencies in converting profit to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.98B	7.79B	7.74B	8.66B	8.38B	8.89B
Gross Profit	3.75B	3.62B	3.54B	4.11B	4.36B	4.49B
EBITDA	397.01M	438.68M	504.84M	575.81M	755.52M	-218.12M
Net Income	-177.67M	64.44M	108.96M	138.26M	238.54M	-601.86M
Balance Sheet
Total Assets	15.25B	15.00B	15.42B	15.71B	14.95B	14.57B
Cash, Cash Equivalents and Short-Term Investments	3.56B	2.95B	3.66B	3.88B	3.23B	2.84B
Total Debt	100.00M	100.00M	130.73M	137.79M	129.14M	171.20M
Total Liabilities	3.55B	3.39B	3.39B	3.80B	3.47B	3.19B
Stockholders Equity	11.70B	11.61B	12.03B	11.91B	11.48B	11.39B
Cash Flow
Free Cash Flow	820.56M	-1.04B	-663.02M	420.76M	-28.97M	-318.82M
Operating Cash Flow	820.56M	-592.45M	-107.34M	631.92M	339.17M	163.44M
Investing Cash Flow	0.00	-13.50M	-2.35M	17.13M	50.57M	-199.51M
Financing Cash Flow	0.00	-103.94M	-104.99M	-1.61M	-1.62M	-3.83M

Wakamoto Pharmaceutical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 289.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4512, the sentiment is Negative. The current price of 289 is above the 20-day moving average (MA) of 288.15, below the 50-day MA of 296.90, and below the 200-day MA of 291.98, indicating a bearish trend. The MACD of -1.89 indicates Negative momentum. The RSI at 46.36 is Neutral, neither overbought nor oversold. The STOCH value of 42.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4512.

Wakamoto Pharmaceutical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4524	―	¥8.68B	18.72	―	2.58%	-0.09%	-29.95%
4539	―	¥6.01B	15.20	―	2.99%	4.25%	―
4538	―	¥18.58B	―	―	3.87%	8.71%	-325.91%
4582	―	¥6.31B	―	―	―	-50.27%	-3.33%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4512	―	¥10.13B	-310.28	―	1.04%	4.00%	-933.04%